Cleared Abbreviated

K103472 - NUFACE PLUS

K103472 is an FDA 510(k) clearance for NUFACE PLUS, manufactured by Carol Cole Company. The device is a Class 2 Neurology device with product code NFO cleared through the Abbreviated 510(k) pathway after a 348-day FDA review.

K103472 · Carol Cole Company · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2011
Decision
348d
Days
Class 2
Risk

K103472 is an FDA 510(k) clearance for the NUFACE PLUS. Classified as Stimulator, Transcutaneous Electrical, Aesthetic Purposes (product code NFO), Class II - Special Controls.

Submitted by Carol Cole Company (Poway, US). The FDA issued a Cleared decision on November 7, 2011 after a review of 348 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5890 - the FDA neurology device framework. The Abbreviated 510(k) pathway was used, relying on FDA-recognized standards to demonstrate substantial equivalence.

Device pattern: Standards-based predicate clearance. Standards-verified equivalence. The Abbreviated pathway signals strong alignment with FDA-recognized performance standards - typically associated with lower review burden and faster clearance cycles.

View all Carol Cole Company devices

FDA 510(k) Submission Details - K103472

510(k) Number K103472 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 24, 2010
Decision Date November 07, 2011
Days to Decision 348 days
Submission Type Abbreviated
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
200d slower than avg
Panel avg: 148d · This submission: 348d
Pathway characteristics
Standards-based clearance path.

NFO Device Classification - Class 2, Special Controls

Product Code NFO Stimulator, Transcutaneous Electrical, Aesthetic Purposes
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5890
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.